Key Takeaways from the RareNRG1FusionMarket. The market size for Rare NRG1 Fusion in the leading markets is expected to grow during the forecast period 2024–2034 ... Key FactorsDriving the Rare NRG1 Fusion Market ... What is Rare NRG1 Fusion?.
Data in NRG1+ Cholangiocarcinoma. The eNRGy trial is a multicenter, open-label, phase 2 study evaluating zenocutuzumab in adults with advanced solid tumors harboring NRG1 gene fusions ...FDA Approval in Three NRG1+ Solid Tumors.